Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 3Phase 2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

fludarabine 9Cyclophosphamide 9pembrolizumab 5Oncolytic Virotherapy 4Nivolumab 4Cholestanetriol 26-Monooxygenase 3atezolizumab 2alpha-Synuclein 2Trastuzumab 2Influenza Vaccines 2Blood Specimen Collection 2Ascorbic Acid 2tinostamustine 1sugemalimab 1spartalizumab 1ruxolitinib 1reolysin 1pexidartinib 1methyl prednisolonate 1irinotecan sucrosofate 1fiu protein, E coli 1camrelizumab 1avelumab 1apatinib 1VTX-2337 1Temozolomide 1TAK-981 1Sorafenib 1Radiation 1RXDX-106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Lisaftoclax × Clear all
NCT03537482 2024-08-19

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase EARLY_PHASE1 Recruiting
90 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡